Assenagon Asset Management S.A. Decreases Holdings in Insulet Co. (NASDAQ:PODD)

Assenagon Asset Management S.A. decreased its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 12.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,836 shares of the medical instruments supplier's stock after selling 12,556 shares during the period. Assenagon Asset Management S.A. owned approximately 0.13% of Insulet worth $24,117,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. bought a new position in shares of Insulet in the fourth quarter worth approximately $42,000. SRS Capital Advisors Inc. grew its holdings in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the last quarter. Finally, Coppell Advisory Solutions LLC grew its holdings in shares of Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after purchasing an additional 162 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Raymond James restated an "outperform" rating and issued a $360.00 target price (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a report on Saturday. Oppenheimer boosted their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Stifel Nicolaus boosted their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, Citigroup restated a "buy" rating and set a $380.00 price target (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $318.41.

Insider Transactions at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Stock Up 0.3%

Insulet stock traded up $1.01 during trading hours on Friday, hitting $304.63. 670,638 shares of the stock traded hands, compared to its average volume of 710,826. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm's 50-day moving average price is $287.15 and its two-hundred day moving average price is $274.95. Insulet Co. has a one year low of $173.00 and a one year high of $329.33. The company has a market cap of $21.44 billion, a PE ratio of 52.61, a PEG ratio of 3.62 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same period in the previous year, the firm posted $0.73 EPS. The business's revenue for the quarter was up 28.8% compared to the same quarter last year. On average, research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.